GLP-1 drugs and A1C: separating real results from TikTok timelines

What did @rejiekay actually say?

Honestly, the spoken transcript here is almost entirely useless for fact-checking. The creator said something along the lines of "why would a bitch like me want to be on the olympic body," which is a passing, self-deprecating reference to Ozempic. It reads like an intro quip, not a medical claim.

The real substance is in the caption. There, @rejiekay describes starting a GLP-1 medication reluctantly, dropping their A1C from 9 to 7.3 in roughly one month, losing over 10 pounds in two months, and crediting the drug with meaningfully improving their type 2 diabetes management. That caption is what we're actually evaluating.

Does the science back this up?

The broad strokes are plausible, and the A1C improvement in particular lines up with what clinical trials have shown. But the timeline is the part that deserves scrutiny.

Semaglutide's SUSTAIN-6 trial (Marso et al., 2016, NEJM) showed A1C reductions averaging around 1.0 to 1.4 percentage points over 104 weeks. The STEP 5 trial (Garvey et al., 2022, Nature Medicine) confirmed sustained glycemic improvement over two years. Neither trial showed changes this dramatic in one month specifically. A1C reflects average blood glucose over approximately three months, so a single-month reading can sometimes skew lower if blood glucose dropped sharply just before the test. That does not make @rejiekay's result impossible, but it means the one-month framing may be compressing a longer trend.

The 10-pound weight loss over two months is more consistent with early-phase GLP-1 response, particularly at higher doses. The STEP 1 trial (Wilding et al., 2021, NEJM) showed average weight loss of roughly 14.9% body weight over 68 weeks, with faster losses early on.

What did they get wrong (or right)?

They got the general outcome right. GLP-1 receptor agonists do meaningfully reduce A1C and support weight loss in people with type 2 diabetes. That is not in dispute. Credit where it is due: they were transparent about their reluctance to start, shared specific numbers instead of vague claims, and explicitly tied the outcome to better diabetes management rather than just aesthetics.

What they got fuzzy on is the one-month A1C attribution. A1C is a lagging indicator. If their reading dropped from 9 to 7.3, some of that improvement almost certainly reflects glucose control from weeks before they started the medication, or reflects a sharp recent drop that makes the three-month average look lower than it truly is. It is not wrong exactly, but presenting a 1.7-point A1C drop as a one-month drug result oversimplifies the measurement. Viewers with diabetes should understand A1C does not update that quickly.

What should you actually know?

GLP-1 agonists are legitimate, well-studied tools for type 2 diabetes management. The FDA has approved semaglutide (Ozempic) specifically for glycemic control in adults with type 2 diabetes, and the evidence base is substantial. This is not a fringe treatment.

That said, individual results vary considerably. A starting A1C of 9 indicates poorly controlled diabetes, and people with higher baseline A1C tend to show larger absolute drops when treatment begins. Do not use one person's numbers as your benchmark.

A follow-up appointment, which @rejiekay mentions planning for March, is exactly the right move. GLP-1 therapy requires ongoing monitoring, dose adjustments, and lab work. A telehealth provider can prescribe and monitor this, but the relationship has to be continuous, not a one-time consult. Anyone seeing this video and considering a GLP-1 for diabetes management should have a provider tracking their A1C, kidney function, and any gastrointestinal side effects regularly.

Bottom line on the "Ozempic body" framing

The throwaway joke about not wanting an "olympic body" is worth addressing directly. GLP-1 medications were developed for metabolic disease, not physique optimization. Conflating the two is a cultural problem that this creator is actually lightly pushing back on, which is fair. People with type 2 diabetes using semaglutide for glycemic control are doing something medically different from healthy individuals using it for cosmetic weight loss. The distinction matters for dosing, monitoring, and risk-benefit calculation.